UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000043472
Receipt number R000049627
Scientific Title The effect of anesthesia-stimulation time on the seizure quality in electroconvulsive therapy: a single-blind, parallel-group, randomized controlled trial
Date of disclosure of the study information 2021/02/28
Last modified on 2021/02/28 20:03:59

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The effect of anesthesia-stimulation time on the seizure quality in electroconvulsive therapy: a single-blind, parallel-group, randomized controlled trial

Acronym

The effect of anesthesia-stimulation time on the seizure quality in ECT: a single-blind, parallel-group, RCT

Scientific Title

The effect of anesthesia-stimulation time on the seizure quality in electroconvulsive therapy: a single-blind, parallel-group, randomized controlled trial

Scientific Title:Acronym

The effect of anesthesia-stimulation time on the seizure quality in ECT: a single-blind, parallel-group, RCT

Region

Japan


Condition

Condition

ECT-adapted disorders such as depression, bipolar disorder, schizophrenia, schizoaffective disorder and catatonia

Classification by specialty

Psychiatry Anesthesiology

Classification by malignancy

Others

Genomic information

YES


Objectives

Narrative objectives1

The time interval from anesthesia to the electrical stimulation (ASTI) indirectly reflects the drug concentration in the brain of the anesthetic and is, therefore, an important factor in determining whether or not a seizure occurs. The time interval from anesthesia to the electrical stimulation (AETI) indirectly reflects the concentration of anesthetic drugs in the brain and is an important factor in determining whether or not a seizure occurs. In this study, the investigators will investigate the relationship between AETI and seizure quality, efficacy, and tolerability in a single-blind, parallel-group study, and evaluate and analyze each context. The aim is to contribute to the optimization of treatment algorithms and the establishment of an effective therapeutic platform so that patients can benefit consistently from ECT.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase



Assessment

Primary outcomes

Seizure Quality in ECT

Key secondary outcomes

Assessment of the severity of each disease


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Single blind -participants are blinded

Control

Dose comparison

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Maneuver

Interventions/Control_1

Anesthesia to stimulation time is 150 seconds

Interventions/Control_2

Anesthesia to stimulation time is 240 seconds

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

16 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) Patients for whom ECT is indicated according to the "ECT Practice Guide" in the APA Task Force Report (main diagnoses for which ECT is indicated: catatonia, major depressive disorder, mania, schizophrenia, etc.)
(2) Patients who have given consent for ECT from the subject himself/herself or a substitute (family member, etc.) at the time of obtaining research consent

Key exclusion criteria

(1) Patients who are judged to be difficult to undergo ECT due to complications such as physical symptoms.
(2) Patients who are judged inappropriate for this study by the physician in charge.

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Nobuatsu
Middle name
Last name Aoki

Organization

Kansai Medical University

Division name

Department of Neuropsychiatry

Zip code

5708506

Address

10-15 Fumizoon-cho, Moriguchi-shi, Osaka prefecture

TEL

0669921001

Email

aokinob@takii.kmu.ac.jp


Public contact

Name of contact person

1st name Aoki
Middle name
Last name Nobuatsu

Organization

Kansai Medical University

Division name

Department of Neuropsychiatry

Zip code

5708596

Address

10-15 Fumizoon-cho, Moriguchi-shi, Osaka prefecture

TEL

09077604177

Homepage URL


Email

aokinob@takii.kmu.ac.jp


Sponsor or person

Institute

Kansai Medical University

Institute

Department

Personal name



Funding Source

Organization

This work was supported by KAKENHI Grants-in-Aid for Scientific Research C (19K08031) from JSPS.

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor

Department of Neuropsychiatry, Graduate School of Medicine, Kyoto University

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Department of Neuropsychiatry, Kansai Medical University

Address

10-15 Fumizoon-cho, Moriguchi-shi, Osaka prefecture

Tel

09077604177

Email

aokinob@takii.kmu.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 02 Month 28 Day


Related information

URL releasing protocol


Publication of results

Partially published


Result

URL related to results and publications

https://nrid.nii.ac.jp/nrid/1000080343672/

Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2018 Year 04 Month 17 Day

Date of IRB

2019 Year 07 Month 09 Day

Anticipated trial start date

2019 Year 07 Month 26 Day

Last follow-up date

2024 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded

2024 Year 03 Month 31 Day


Other

Other related information



Management information

Registered date

2021 Year 02 Month 28 Day

Last modified on

2021 Year 02 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049627


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name